Browse the evidence

Higher low carbohydrate diet (LCD) score is associated with an increased risk of type 2 diabetes (T2D), with a 20% increased risk observed when comparing the highest quintile (38% energy from carbohydrates) to the lowest quintile (55% energy from carbohydrates).

Practitioners should be cautious when recommending low carbohydrate diets, as they may increase the risk of type 2 diabetes, particularly in individuals with higher body weight.

The association between low carbohydrate diet score and diabetes risk is largely explained by obesity, with BMI mediating 76% of the association.

Understanding the role of BMI in the relationship between low carbohydrate diets and diabetes risk can help tailor dietary recommendations.

Obesity-targeted interventions are a novel treatment strategy for heart failure with preserved ejection fraction (HFpEF).

Healthcare providers should explore obesity-targeted interventions in managing HFpEF.

After 6 months of semaglutide treatment, participants showed significant reductions in Psoriasis Area and Severity Index (PASI) by 48%, body mass index (BMI), and preperitoneal and superficial fat.

Semaglutide may be an effective treatment for improving psoriasis severity in obese patients.

Semaglutide treatment is associated with improvements in quality of life (DLQI) and depressive symptoms (BDI) after 6 months.

Improving psoriasis treatment may also enhance mental health and quality of life.

Tirzepatide may provide additional benefits beyond glycemic control for T2DM patients.

Tirzepatide may be beneficial for T2DM patients in ways beyond just lowering blood sugar.

Emerging evidence suggests that combining IF and KD may offer synergistic metabolic effects.

Practitioners may explore the combination of IF and KD for enhanced metabolic benefits in patients.

Observational data suggest GLP-1 RAs improve walking distance in peripheral artery disease.

GLP-1 RAs may enhance mobility in patients with peripheral artery disease.

Lifestyle modifications remain the primary approach to managing MASLD, but their effectiveness is often limited.

Practitioners should be aware of the limitations of lifestyle modifications in MASLD management.

Incretin analogs are preferred for overweight or obese patients according to the American Gastroenterological Association.

Providers should consider these guidelines when treating overweight or obese patients.

Nutritional therapists are too rarely consulted despite the significant effects of diet on cardiovascular risk factors.

Practitioners should consider involving nutritional therapists in treatment plans for dyslipidemias.

Recent studies support the plausibility and evidence of individual nutritional measures for dyslipidemias.

Practitioners should stay updated on recent studies regarding nutritional interventions for dyslipidemias.

Weight gain increases the risk for atherosclerosis regardless of cardiovascular events status or overweight/obese at baseline.

Practitioners should be aware that weight gain is a significant risk factor for atherosclerosis.

A higher proportion of carbohydrate intake is associated with an increased risk of cardiovascular disease and all-cause mortality in Japanese people with type 2 diabetes.

Practitioners should consider the carbohydrate intake levels of patients with type 2 diabetes when assessing cardiovascular risk.

The mean total low-carbohydrate diet score and animal low-carbohydrate diet score are inversely associated with the incidence of cardiovascular events and all-cause mortality.

Encouraging low-carbohydrate dietary patterns may benefit patients with type 2 diabetes in reducing cardiovascular risk.

The study utilized a multivariable Cox proportional hazards model to analyze the relationship between lifestyle habits and health outcomes.

Understanding the methodology can help practitioners evaluate the reliability of the findings.

Resistance training practitioners frequently consume excessive protein and protein supplements (primarily whey) driven by aesthetic goals, despite evidence that intakes above ~1.6 g/kg/day do not further increase muscle mass.

You likely do not need protein supplements to build muscle. Focus on getting 1.6 grams of protein per kilogram of body weight daily from whole foods. If you are already hitting this number through food, adding whey protein powder provides no additional muscle-building benefit and wastes money. Prioritize carbohydrates for energy during workouts instead.

GLP-1 agonists may provide additional benefits beyond weight loss and diabetes management.

Providers should explore the broader implications of GLP-1 agonists for patients with various conditions.

Combining GLP-1 RAs with EBTs may yield synergistic effects.

Practitioners may explore combination therapies for enhanced weight loss outcomes.

72.2% of patients achieved ≥ 20% total weight loss (TWL) by week 52 on liraglutide.

Practitioners can expect a significant proportion of patients to achieve substantial weight loss with liraglutide.

Liraglutide was well-tolerated, with benefits experienced by over 90% of patients.

Liraglutide can be considered a safe option for obesity management in clinical practice.

Patients achieved a calorie deficit of 651 kcal/day while on liraglutide.

Practitioners should encourage calorie tracking to support weight loss efforts in patients using liraglutide.

Individuals without diabetes were more likely to achieve ≥10% weight loss compared to individuals with T2D (21.4% vs. 0%).

Practitioners may consider the likelihood of achieving significant weight loss when prescribing tirzepatide based on diabetes status.

The basic principles of healthy nutrition remain largely unchanged over the years.

Practitioners should focus on established nutritional guidelines rather than trends.